{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-113362","form_type":"8-K","ticker":"CLSDQ","cik":"0001539029","company_name":"Clearside Biomedical, Inc.","filed_at":"2025-09-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.278054+00:00","generated_at":"2026-05-17T07:34:55.576772+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Clearside Biomedical receives additional $3M from Healthcare Royalty; reduces royalty cap","bullets":["Company entered Omnibus Amendment with Healthcare Royalty Partners; received $3.0M for remaining SCS Microinjector assets.","Royalty threshold for expiration reduced from $110.5M to $106.5M; potential lower future payments.","Purchaser waived right to foreclose on Seller capital stock in specified circumstances.","All other terms of original 2022 Purchase/Sale and Contribution Agreements remain unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-113362","json":"https://secwatch.observer/filing/0000950170-25-113362.json","markdown":"https://secwatch.observer/filing/0000950170-25-113362.md","text":"https://secwatch.observer/filing/0000950170-25-113362.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1539029/000095017025113362/0000950170-25-113362-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1539029/000095017025113362/clsd-20250904.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T07:34:55.576772+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}